Funding Layoffs Pricing Study 
Xconomy
OCTOBER 7, 2016
. —Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. The funding could be as much as $100 million, and the first grants will be announced in 2017. PRICE FIGHTS. —The U.S.
Xconomy
JANUARY 25, 2019
In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.
Xconomy
JUNE 30, 2017
There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.
Expert insights. Personalized for you.
77 
Let's personalize your content